UPDATE: Vivos Therapeutics (VVOS) Could Change the Lives of 22M US Adults, Craig-Hallum Starts at Buy Ahead of Stanford Trial Data

(Updated - January 11, 2021 8:41 AM EST)

Craig-Hallum analyst Alex Nowak initiates coverage on Vivos Therapeutics (NASDAQ: VVOS) with a Buy rating and a price target of $12.00 ahead of results from a Stanford based randomized study that, if successful, would boost adoption, and could potentially make Vivos the standard of care in a $35B market. The company is commercializing an alternative, noninvasive and potentially permanent solution to mild-moderate Obstructive Sleep Apnea (OSA). The current treatments, although effective, are costly, extremely burdensome and used for life. Vivos developed an oral appliance that remodels the lower jaw and nasal cavities, much like Invisalign remodels tooth alignment. After remodeling the result is a treatment for OSA. There are ~22M U.S. adults with OSA. Vivos is validated and adoption is ramping.

The analyst stated "VVOS developed a novel solution in treating OSA. VVOS’ device is called the mRNA Appliance; it ditches lifetime care and non-invasively remodels the mandibular region over 12-24 months to treat the underlying cause of OSA. The Invisalign-esque device is more affordable, convenient and improves sleep apnea scores by ~64% (in line with CPAP). Dentists say it is a permanent solution and “changes patients’ lives.”"

For an analyst ratings summary and ratings history on Vivos Therapeutics click here. For more ratings news on Vivos Therapeutics click here.

Shares of Vivos Therapeutics closed at $6.23 yesterday.

You May Also Be Interested In

• Loop Capital Starts Instacart (CART) at Buy, 'Leading a Massive and Underpenetrated Category'
• JMP Securities Starts The RMR Group Inc. (RMR) at Market Perform, 'Pure-Pay'
• Badger Meter (BMI) PT Raised to $184 at Deutsche Bank